(Q36274391)

13 August 2017

1 reference

title

Modulation of cytochrome P450 activity: implications for cancer therapy (English)

1 reference

13 August 2017

2

Alex Sparreboom

1 reference

13 August 2017

Charity D Scripture

1

1 reference

PubMed ID

16198984

13 August 2017

William D Figg

series ordinal

3

1 reference

13 August 2017

1 October 2005

1 reference

Lancet Oncology Commission

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

10

1 reference

13 August 2017

780-789

1 reference

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Pharmacogenomics--drug disposition, drug targets, and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Tumour cytochrome P450 and drug activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Tumor-activated prodrugs--a new approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

From bench to bedside for gene-directed enzyme prodrug therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

The influence of age and sex on the clearance of cytochrome P450 3A substrates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Drug metabolism in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Drug metabolism and ageing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Sex is a major determinant of CYP3A4 expression in human liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Hepatic drug metabolism and aging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Bioequivalence revisited: influence of age and sex on CYP enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Hepatic cytochrome P-4503A (CYP3A) activity in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Pharmacokinetics of anticancer agents in patients with impaired liver function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Factors affecting cytochrome P-450 3A activity in cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Cancer pharmacogenetics: polymorphisms, pathways and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Drug interactions in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Role of P-glycoprotein in pharmacokinetics: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Metabolism and pharmacokinetics of oxazaphosphorines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Effects of inducer of liver drug-metabolizing enzyme on blood level of active metabolites of cyclophosphamide in rats and in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

1 reference

7 January 2021

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Clinical pharmacokinetics of docetaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Noninvasive tests of CYP3A enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Pharmacogenetics of irinotecan toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Modulation of irinotecan metabolism by ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Effects of St. John's wort on irinotecan metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970388-0

7 January 2021

10.1016/S1470-2045(05)70388-0

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16198984